Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 70.91M shares outstanding
USSagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition. These treatments are engineered to combat medical conditions stemming from impaired lipid metabolism pathways.
Its primary investigational compound, Denifanstat, is a FASN inhibitor currently being evaluated for nonalcoholic steatohepatitis (NASH) and acne.
Additionally, Sagimet is advancing TVB-3567, another FASN inhibitor, which targets various forms of cancer. Founded in 2006, the company's main operations are located in San Mateo, California.
It was formerly recognized as 3-V Biosciences, Inc. until it rebranded to Sagimet Biosciences Inc. in August 2019.
ANNE PHILLIPS, M.D.
Director
Andreas Grauer, M.D.
Chief Medical Officer
David Happel
President, Chief Executive Officer and Director
Elizabeth Grammer, Esq.
Director
Employees
14
Country
US
Sector
Healthcare
Website
sagimet.com
Loading congressional disclosures…
based on 70.91M shares outstanding
US30d Avg
1.45M
60d Avg
1.29M
90d Avg
1.24M
